Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784118 | 0.82 | GRM5 (0.49) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL6790973 | 0.79 | GRM5 (0.47) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL13997952 | 0.79 | GRM5 (0.42) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL12998397 | 0.78 | HSD17B2 (0.41) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL20364509 | 0.78 | GRM5 (0.51) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL30172141 | 0.78 | FFAR1 (0.44) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL31046512 | 0.78 | KCNH2 (0.46) | GRM5TSHRPTGES | |
| SCHEMBL14177743 | 0.78 | HSD17B2 (0.43) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL6132140 | 0.77 | GRM5 (0.66) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL30707880 | 0.77 | GRM5 (0.66) | FFAR1GRM5CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720342-B2 | AZABICYCLIC COMPOUNDS USED IN TREATING A DISEASE IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM. | NOVO NORDISK A/S (DK) | 2004-04-13 | — | — | US | disclosed |
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-6187798-B1 | (+-)EXO-3-(3-(4-CHLOROPHENYL)PROPYNYLOXY-4-(1 -AZABICYCLO(2.2.1)HEPTYL-3-OXY)-1,2,5-THIADIAZOLE, FOR EXAMPLE; FOR MODULATING A MUSCARINIC RECEPTOR; TREATING ALZHEIMER'S DISEASE OR PSYCHOSIS | ELI LILLY AND COMPANY | 2001-02-13 | — | — | US | disclosed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0888355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034899-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | CHRM5, ACHE, CHRM2 | FFAR1 2321/4885GRM5 107/4885CA12 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.